- Home
- BIDU vs INM Comparison
BIDU vs INM Comparison
Compare BIDU & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$91.40
HOLD
Current Price
$1.29
Company Overview
Basic Information| Metric | BIDU | INM |
|---|---|---|
| Founded | 2000 | 1981 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.4B | 7.7M |
| IPO Year | 2005 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BIDU | INM |
|---|---|---|
| Price | $91.40 | $1.29 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $154.38 | N/A |
| AVG Volume (30 Days) | ★ 3.2M | 66.3K |
| Earning Date | 05-18-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.68 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,942,633.00 |
| Revenue This Year | $5.11 | N/A |
| Revenue Next Year | $7.44 | N/A |
| P/E Ratio | $42.45 | ★ N/A |
| Revenue Growth | N/A | ★ 7.50 |
| 52 Week Low | $89.60 | $0.58 |
| 52 Week High | $165.30 | $2.50 |
Technical Indicators
Market Signals| Indicator | BIDU | INM |
|---|---|---|
| Relative Strength Index (RSI) | 35.87 | 36.87 |
| Support Level | $89.60 | $1.03 |
| Resistance Level | $129.93 | $1.40 |
| Average True Range (ATR) | 1.96 | 0.08 |
| MACD | 0.17 | -0.01 |
| Stochastic Oscillator | 10.69 | 5.97 |
Price Performance
Historical Comparison BIDU
INM
About BIDU Baidu Inc. ADS
Most of Baidu's revenue comes from Baidu core, with the rest coming from video-streaming subsidiary iQiyi. The firm's main businesses include online marketing services from its search engine, AI cloud infrastructure, AI applications, AI marketing, and autonomous driving.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.